Palvella Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Palvella Therapeutics, Inc. (PVLA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$3.66 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-11-07
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-09-30 was $53.40M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-06-30 was -$48.76M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$8.29M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$44.74M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$45.88M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$560.00K.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$620.75K.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$267.41K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-09-30 | $53.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $4.63M derived: sum of 2 quarters · filed 2018-11-07 | -$3.66M 10-Q · filed 2018-11-07 | -$48.40M derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2018-06-30 | -$48.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$57.06M 10-Q · filed 2018-08-09 | -$101.80M derived: sum of 3 quarters · filed 2018-08-09 | -$102.09M derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2018-03-31 | -$8.29M 10-Q · filed 2018-05-10 | -$53.04M derived: sum of 2 quarters · filed 2018-05-10 | -$53.33M derived: sum of 3 quarters · filed 2018-11-07 | -$53.99M derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2017-12-31 | -$44.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$45.03M derived: sum of 2 quarters · filed 2018-11-07 | -$45.70M derived: sum of 3 quarters · filed 2018-11-07 | -$45.88M 10-K · filed 2018-03-15 | ||||
| 2017-09-30 | -$289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$952.00K derived: sum of 2 quarters · filed 2018-11-07 | -$1.13M 10-Q · filed 2018-11-07 | -$1.13M 10-Q · filed 2017-11-13 | -$1.37M derived: sum of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | -$663.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$842.00K 10-Q · filed 2018-08-09 | -$842.41K 10-Q · filed 2017-08-11 | -$1.08M derived: sum of 3 quarters · filed 2018-08-09 | -$1.28M derived: sum of 4 quarters · filed 2018-08-09 | |||
| 2017-03-31 | -$179.00K 10-Q · filed 2018-05-10 | -$179.07K 10-Q · filed 2017-05-15 | -$416.29K derived: sum of 2 quarters · filed 2018-05-10 | -$614.39K derived: sum of 3 quarters · filed 2018-05-10 | -$671.08K derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | -$237.29K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$435.39K derived: sum of 2 quarters · filed 2018-03-15 | -$492.08K derived: sum of 3 quarters · filed 2018-03-15 | -$560.00K 10-K · filed 2018-03-15 | -$559.67K 10-K · filed 2017-03-30 | |||
| 2016-09-30 | -$198.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$254.79K derived: sum of 2 quarters · filed 2017-11-13 | -$322.71K 10-Q · filed 2017-11-13 | -$674.19K derived: sum of 4 quarters · filed 2017-11-13 | ||||
| 2016-06-30 | -$56.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | -$124.61K 10-Q · filed 2017-08-11 | -$476.09K derived: sum of 3 quarters · filed 2017-08-11 | -$671.07K derived: sum of 4 quarters · filed 2017-08-11 | ||||
| 2016-03-31 | -$67.92K 10-Q · filed 2017-05-15 | -$419.40K derived: sum of 2 quarters · filed 2017-05-15 | -$614.38K derived: sum of 3 quarters · filed 2017-05-15 | -$648.02K derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | -$351.48K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$546.46K derived: sum of 2 quarters · filed 2017-03-30 | -$580.10K derived: sum of 3 quarters · filed 2017-03-30 | -$620.75K 10-K · filed 2017-03-30 | ||||
| 2015-09-30 | -$194.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$228.62K derived: sum of 2 quarters · filed 2016-11-10 | -$269.26K 10-Q · filed 2016-11-10 | -$522.36K derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | -$33.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$74.29K 10-Q · filed 2016-08-11 | -$72.29K 10-Q · filed 2015-08-13 | -$327.38K derived: sum of 3 quarters · filed 2016-08-11 | -$336.73K derived: sum of 4 quarters · filed 2016-08-11 | |||
| 2015-03-31 | -$40.65K 10-Q · filed 2016-05-12 | -$293.74K derived: sum of 2 quarters · filed 2016-05-12 | -$303.09K derived: sum of 3 quarters · filed 2016-05-12 | -$306.29K derived: sum of 4 quarters · filed 2016-05-12 | ||||
| 2014-12-31 | -$253.09K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | -$262.44K derived: sum of 2 quarters · filed 2016-03-23 | -$265.64K derived: sum of 3 quarters · filed 2016-03-23 | -$267.41K 10-K · filed 2016-03-23 | ||||
| 2014-09-30 | -$9.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$12.54K derived: sum of 2 quarters · filed 2015-11-13 | -$14.31K 10-Q · filed 2015-11-13 | |||||
| 2014-06-30 | -$3.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$4.96K 10-Q · filed 2015-08-13 | ||||||
| 2014-03-31 | -$1.77K 10-Q · filed 2015-05-14 | |||||||
| 2013-12-31 | -$49.47K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |